The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); CV6 Therapeutics (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CV6 Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Exscientia (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Moderna Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - iOnctura (Inst); Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai; Roche
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Ono Pharmaceutical; Roche
 
Lucjan S. Wyrwicz
Honoraria - BeiGene; BMS; MSD
Consulting or Advisory Role - GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS
Travel, Accommodations, Expenses - SERVIER
 
Roger KC Ngan
Consulting or Advisory Role - AstraZeneca; Eisai; Fosun Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Zai Lab
Speakers' Bureau - AstraZeneca; Eisai; Fosun Pharma; Gilead Sciences; Lilly; MSD Oncology; Novartis; Zai Lab
Travel, Accommodations, Expenses - Novartis
 
Jean-Frédéric Blanc
Honoraria - AstraZeneca; Bayer Schering Pharma; Eisai; INCYTE; IPSEN; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IPSEN; ROCHE; SERVIER; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca; IPSEN; Roche
 
Ari David Baron
Speakers' Bureau - Bristol-Myers Squibb; Lilly
 
Arndt Vogel
Honoraria - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; EISAI; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Fabio Piscaglia
Consulting or Advisory Role - AstraZeneca; Eisai; Exact Sciences; MSD; Nerviano Medical Sciences; Roche; Siemens Healthineers
Speakers' Bureau - AstraZeneca; Bayer; Bracco Diagnostics; Eisai; Esaote; GE Healthcare; Ipsen; MSD; Roche; Samsung
Travel, Accommodations, Expenses - AstraZeneca; Siemens Healthineers
 
Shukui Qin
No Relationships to Disclose
 
Taisuke Hoshi
Employment - Eisai
Stock and Other Ownership Interests - Chugai Pharma (I); Daiichi Sankyo Company (I); Eisai; Eisai (I)
Patents, Royalties, Other Intellectual Property - Under submission and review
 
Ryuji Tamaki
Employment - Kaneka Corporation (I)
 
Yasuhiro Funahashi
Employment - Eisai
 
Chinyere E Okpara
Employment - Eisai
 
Koji Sagane
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Dongyuan Xing
Employment - Eisai
 
Yukinori Minoshima
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Medivir; Medivir; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)